Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,122,776
  • Shares Outstanding, K 637,220
  • Annual Sales, $ 22,849 M
  • Annual Income, $ 1,979 M
  • 36-Month Beta 1.41
  • Price/Sales 5.36
  • Price/Cash Flow 12.45
  • Price/Book 8.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 3.25
  • Number of Estimates 10
  • High Estimate 3.33
  • Low Estimate 3.15
  • Prior Year 2.89
  • Growth Rate Est. (year over year) +12.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
186.26 +0.34%
on 12/18/18
208.99 -10.57%
on 11/30/18
-7.29 (-3.75%)
since 11/16/18
3-Month
181.31 +3.08%
on 10/25/18
210.19 -11.09%
on 09/27/18
-15.45 (-7.64%)
since 09/18/18
52-Week
163.31 +14.44%
on 04/02/18
210.19 -11.09%
on 09/27/18
+10.75 (+6.10%)
since 12/18/17

Most Recent Stories

More News
S&P 500 Q3 2018 Buybacks Surpass $200 Billion Mark for the First Time Ever

S&P Dow Jones Indices ("S&P DJI") announced today that preliminary Q3 2018 S&P 500® stock buybacks, or share repurchases, surpassed the $200 billion mark for the first time to set a record $203.8 billion....

GOOG : 1,033.99 (+1.72%)
AAPL : 165.51 (+0.96%)
CSCO : 43.98 (-0.50%)
C : 53.92 (-0.61%)
BAC : 24.41 (-0.25%)
JPM : 98.47 (-0.55%)
ORCL : 45.91 (+0.39%)
AMGN : 186.38 (-1.95%)
MSFT : 103.31 (+0.41%)
SBUX : 65.07 (+0.93%)
QCOM : 57.91 (+1.60%)
WFC : 46.54 (-0.15%)
INTC : 47.70 (+1.32%)
WBA : 75.96 (-0.34%)
LRCX : 138.61 (+2.16%)
SPGI : 167.98 (+1.02%)
FB : 143.94 (+2.67%)
HD : 169.85 (+1.12%)
BKNG : 1,776.46 (+2.12%)
BA : 329.31 (+4.17%)
WMT : 90.65 (-0.13%)
Merck's Keytruda Gets EU Nod as Adjuvant Therapy for Melanoma

Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.

MRK : 74.00 (-1.63%)
RHHBY : 30.9700 (-0.26%)
AMGN : 186.38 (-1.95%)
BMY : 51.42 (+0.98%)
Teva Reports Positive Top-Line Data for Migraine Candidate

Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.

LLY : 106.45 (-1.76%)
NVS : 85.24 (-0.61%)
TEVA : 17.23 (-2.38%)
AMGN : 186.38 (-1.95%)
Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod

Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).

RHHBY : 30.9700 (-0.26%)
AMGN : 186.38 (-1.95%)
PFE : 42.29 (-1.90%)
BMY : 51.42 (+0.98%)
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab)....

AMGN : 186.38 (-1.95%)
Stocks plunge to 8-month lows on growth fears; J&J nosedives

NEW YORK (AP) — Stocks staggered to eight-month lows Friday after weak economic data from China and Europe set off more worries about the global economy. Mounting tensions in Europe over Britain's impending...

SBUX : 65.07 (+0.93%)
JNJ : 130.57 (+1.11%)
ADBE : 225.83 (+2.01%)
AMGN : 186.38 (-1.95%)
PFE : 42.29 (-1.90%)
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric...

AMGN : 186.38 (-1.95%)
Look for Shares of Amgen Inc to Potentially Rebound after Yesterday's 1.60% Sell Off

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $193.42 to a high of $196.10. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $194.34...

AMGN : 186.38 (-1.95%)
5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.

MRK : 74.00 (-1.63%)
JNJ : 130.57 (+1.11%)
LLY : 106.45 (-1.76%)
VRTX : 162.94 (-1.94%)
RHHBY : 30.9700 (-0.26%)
AMGN : 186.38 (-1.95%)
BIIB : 291.46 (-6.91%)
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

AVEO : 1.76 (-7.85%)
ANIK : 31.84 (-0.28%)
VVUS : 3.01 (+5.61%)
INCY : 64.14 (-1.05%)
EXEL : 20.00 (-4.03%)
GILD : 64.82 (-0.46%)
AMGN : 186.38 (-1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 196.87
1st Resistance Point 193.47
Last Price 186.38
1st Support Level 187.66
2nd Support Level 185.25

See More

52-Week High 210.19
Fibonacci 61.8% 192.28
Fibonacci 50% 186.75
Last Price 186.38
Fibonacci 38.2% 181.22
52-Week Low 163.31

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar